Toceranib (INN[2]), sold under the brand name Palladia, is a receptor tyrosine kinase inhibitor that is used in the treatment of canine mast cell tumor also called mastocytoma.

[3] It is the first medication developed specifically for the treatment of cancer in dogs.

It was developed by SUGEN as SU11654,[6] a sister compound to sunitinib, which was later approved for human therapies.

[4] Toceranib is indicated to treat canine cutaneous (skin-based) mast cell tumors, a type of cancer responsible for about one out of five cases of canine skin tumors.

[4] It is approved to treat the tumors with or without regional lymph node involvement.